Psychedelic Science 2023

Be Part of

        the Breakthrough

Presented by

The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder

PS2023-222-tn

The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder

More than 17 million people in the U.S. live with cancer and up to 25% of them have major depression. Depression leads to lower treatment adherence, reduced quality of life, and higher rates of mortality in cancer. Yet, interventions used to treat depression in patients with cancer have limited success. Prior trials using psilocybin to treat anxiety and depression associated with cancer suggested improvements in psychological distress. However, treatment in a homogenous psychiatric sample has yet to be investigated. Further, psilocybin has not been given in groups, and in a setting conducive to the “whole person” approach to treatment. This trial built upon previous studies and tested the safety, feasibility, and efficacy of psilocybin therapy in cancer patients diagnosed with major depressive disorder (MDD), with the novel use of group treatment in a cancer center setting. https://clinicaltrials.gov/ct2/show/NCT04593563

Share: The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder

Facebook
Twitter
LinkedIn
Email

Already Registered?

If you already registered for the in-person portion of the Psychedelic Science 2023 conference, get immediate access to PS2023: The Virtual Trip by logging in with the email address you used when signing up for the conference. We’ll email you a login link—no password necessary!

Need to Register?

If you are not yet registered for Psychedelic Science 2023, you can sign up for PS2023: The Virtual Trip access by creating an account.